Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today published the invitation to the Annual General Meeting 2026 and announced the nomination of Clare Fisher for election as a new member of the Board of Directors (BoD) at the Annual General Meeting.

The Annual General Meeting will be held on Tuesday, April 14, 2026, 9:00 am CET (doors open at 8:30 am CET), at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland.

Invitation to the Annual General Meeting 2026 with the corresponding agenda items.

Einladung zur Generalversammlung 2026 mit den zugehörigen Traktandenpunkten.

“We are pleased to propose Clare Fisher for election to our BoD. Clare brings extensive leadership experience in business and corporate development in the biotech and pharmaceutical industry, and we believe her strategic and hands-on skillsets will be valuable for our partnerships and for our growing pipeline of innovative therapeutics,” said Bill Burns, Chairman of the Board of Directors of Molecular Partners.

Clare Fisher is currently the SVP for Global Business Development and M&A at BeOne Medicines, global oncology company committed to discovering and developing innovative treatments for cancer patients worldwide. Clare has more than two decades of healthcare experience in leadership roles, including corporate and business development, mergers and acquisitions, and strategy. She joined BeOne from Kaleido, where she served as Chief Business Officer. Previously she worked at Shire plc (now Takeda), where she was Group Vice President, Global Head of Transactions and Business Development, and Interim Head of Corporate Development. She also held senior roles in business development at Cubist Pharmaceuticals, Blueprint Medicines, and Genzyme Corporation. Clare Fisher earned B.S. in biochemistry from the University of Bath and an MBA from Henley Management College in the U.K.

Current Board member Steven H. Holtzman will not stand for re-election following 12 years of service on the BoD of Molecular Partners.

“On behalf of Molecular Partners, I want to express my deepest gratitude to Steven for his twelve years of outstanding service on our Board. His strategic guidance and hands-on BD support were instrumental in securing our first pharma partnership, he supported our Swiss IPO and US listing and was there with us during the unprecedented challenge to make a COVID drug. His personal trust and unwavering support have meant a lot to the company and to me personally,” said Patrick Amstutz, CEO of Molecular Partners. “We thank him sincerely for his exceptional dedication and lasting contributions to Molecular Partners.”

Bill Burns added: “On behalf of my colleagues, I would like to sincerely thank Steven Holtzman for his service and dedication to Molecular Partners as a Board member over the last 12 years. During this time, Steven has provided invaluable advice and strategic guidance on the development of the Company’s business and portfolio to deliver on the potential of DARPin therapeutics for patients. We wish him all the best for his future endeavors.”

Financial calendar

The latest timing of the above events can always be viewed on the investor section of the website.